hrp0095p1-484 | Fat, Metabolism and Obesity | ESPE2022

Suboptimal adherence to statin therapy in children and adolescents with HeFH despite a high therapeutic efficacy: is the cardiovascular risk underestimated?

Bruzzi Patrizia , Di Martino Marianna , Di Caprio Antonella , Filomena Madeo Simona , Lucaccioni Laura , Predieri Barbara , Iughetti Lorenzo

Background: Heterozygous familial hypercholesterolemia (HeFH) is characterized by severely elevated low-density lipoprotein cholesterol (LDL-C) levels and premature cardiovascular disease. European guidelines currently support the initiation of statin therapy by age 8-10 years in patients with HeFH to slow the progression of endothelial disfunction and to reduce the risk of cardiovascular disease in adulthood. However, to date, there is lack of data on adheren...